Peer-reviewed veterinary case report
New vaccine using vaccinia virus triggers immune response to canine
By Zhao, Wanbo et al.·Published in Viral immunology·2020·Wuhan University of Bioengineering, China·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Administration with Vaccinia Virus Encoding Canine Parvovirus 2Elicits Systemic Immune Responses in Mice and Dogs.
- Species:
- dog
Plain-English summary
A group of young dogs was given a new vaccine made from a modified virus to protect against canine parvovirus (CPV2), a serious and often deadly disease. This new vaccine showed strong immune responses, similar to those from the standard CPV2 vaccine, and did not cause significant side effects. After just one dose, the dogs produced a good amount of antibodies, suggesting they were well-protected against the virus. This promising vaccine could offer a safer and more effective way to prevent CPV2 infections in dogs.
People also search for: dog parvovirus vaccine · canine parvovirus symptoms · new vaccine for dogs parvovirus
Abstract
Canine parvovirus type 2 (CPV2) is a highly contagious cause of serious and often fatal disease in young dogs. Despite the widespread availability of attenuated vaccines, safer, more stable, and more effective CPV2 vaccine candidates are still under exploration. Vaccinia virus (VV) has already been proved to be a safe, stable, and effective vaccine vector. In this study, we generated a VV-based CPV2 vaccine candidate (VV) and then evaluated its immunogenicity in mice and dogs. The exogenousgene of CPV2, which replaced the major virulence gene hemagglutinin () of VV, expressed efficiently and stably. Subsequently, intramuscular immunization of mice induced robust and lasting systemic immune responses, including neutralizing antibody against both CPV2a and CPV2b, and CPV2-VP2-specific interferon gamma (IFN-) secreting T cell. In addition, administration with a high-dose of VVdid not cause significant side effects for mice, thus indicating marked safety of this vaccine candidate. Most importantly, a single-dose vaccination of VVelicited substantial antibody responses and provided comparable protection for dogs with attenuated CPV2 vaccine. Collectively, this study demonstrated that VVcould be used as a promising vaccine candidate preventing CPV2 from infection for dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32364832/